Profile data is unavailable for this security.
About the company
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
- Revenue in USD (TTM)0.00
- Net income in USD-68.87m
- Incorporated2020
- Employees159.00
- LocationNuvation Bio Inc357 Tehama Street, Floor 3SAN FRANCISCO 94103United StatesUSA
- Phone+1 (415) 754-3517
- Fax+1 (302) 636-5454
- Websitehttps://www.nuvationbio.com/
More ▼
Mergers & acquisitions
| Acquired company | NUVB:NYQ since announced | Transaction value |
|---|---|---|
| AnHeart Therapeutics Inc | 41.99% | 100.69m |
Data delayed at least 15 minutes, as of May 22 2024 21:10 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Longboard Pharmaceuticals Inc | 0.00 | -57.95m | 767.10m | 50.00 | -- | 2.45 | -- | -- | -2.25 | -2.25 | 0.00 | 8.07 | 0.00 | -- | -- | 0.00 | -28.45 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Cogent Biosciences Inc | 0.00 | -212.17m | 767.78m | 164.00 | -- | 3.84 | -- | -- | -2.47 | -2.47 | 0.00 | 4.42 | 0.00 | -- | -- | 0.00 | -57.40 | -49.53 | -62.27 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| ALX Oncology Holdings Inc | 0.00 | -166.20m | 781.50m | 74.00 | -- | 4.59 | -- | -- | -3.71 | -3.71 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -67.73 | -34.34 | -76.12 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.067 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Wave Life Sciences Ltd | 112.91m | -61.67m | 788.64m | 266.00 | -- | 31.03 | -- | 6.98 | -0.5152 | -0.5152 | 0.9985 | 0.2719 | 0.4494 | -- | -- | 424,488.70 | -24.54 | -56.98 | -60.43 | -102.38 | -- | -- | -54.61 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Tango Therapeutics Inc | 37.23m | -111.65m | 789.59m | 140.00 | -- | 2.98 | -- | 21.21 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Aurinia Pharmaceuticals Inc | 191.41m | -62.56m | 790.90m | 300.00 | -- | 2.21 | -- | 4.13 | -0.4363 | -0.4363 | 1.34 | 2.50 | 0.3953 | 0.6008 | 7.98 | 638,023.30 | -12.92 | -25.97 | -14.63 | -28.24 | 88.78 | -- | -32.69 | -137.64 | 5.05 | -- | 0.1843 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Evolus Inc | 219.70m | -60.00m | 810.18m | 279.00 | -- | 43.69 | -- | 3.69 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Viridian Therapeutics Inc | 288.00k | -218.13m | 810.55m | 96.00 | -- | 2.12 | -- | 2,814.39 | -4.50 | -4.50 | 0.0058 | 9.13 | 0.0006 | -- | 2.50 | 3,063.83 | -42.89 | -55.59 | -45.38 | -60.32 | -- | -- | -75,737.84 | -5,678.12 | -- | -- | 0.0337 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| Nuvation Bio Inc | 0.00 | -68.87m | 810.72m | 159.00 | -- | 1.21 | -- | -- | -0.3146 | -0.3146 | 0.00 | 2.71 | 0.00 | -- | -- | 0.00 | -10.84 | -16.27 | -11.09 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
| Disc Medicine Inc | 0.00 | -80.60m | 820.01m | 74.00 | -- | 2.42 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| Stoke Therapeutics Inc | 7.85m | -108.53m | 824.02m | 110.00 | -- | 5.24 | -- | 105.04 | -2.42 | -2.42 | 0.1747 | 3.02 | 0.0322 | -- | 31.19 | 71,318.18 | -44.57 | -31.62 | -51.70 | -33.92 | -- | -- | -1,383.40 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| CARGO Therapeutics Inc | 0.00 | -121.21m | 827.29m | 116.00 | -- | 2.22 | -- | -- | -2.91 | -2.91 | 0.00 | 9.48 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| ProKidney Corp | 0.00 | -35.30m | 838.75m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 850.74m | 168.00 | -- | -- | -- | 20.97 | -3.36 | -3.36 | 0.5934 | -- | -- | -- | -- | 241,428.60 | -- | -47.40 | -- | -54.18 | -- | -- | -506.16 | -- | -- | -- | -- | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Pliant Therapeutics Inc | 248.00k | -170.74m | 855.42m | 158.00 | -- | 1.96 | -- | 3,449.28 | -2.86 | -2.86 | 0.0042 | 7.25 | 0.0004 | -- | 0.0701 | 1,569.62 | -30.50 | -33.24 | -32.04 | -35.39 | -- | -- | -68,847.98 | -360.29 | -- | -- | 0.0642 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
Data as of May 22 2024. Currency figures normalised to Nuvation Bio Inc's reporting currency: US Dollar USD
38.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 27.74m | 12.72% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 19.21m | 8.81% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 10.47m | 4.80% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 7.42m | 3.41% |
| Abrams Capital Management LPas of 31 Mar 2024 | 3.81m | 1.75% |
| Tang Capital Management LLCas of 31 Mar 2024 | 3.55m | 1.63% |
| Geode Capital Management LLCas of 31 Mar 2024 | 3.13m | 1.43% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.04m | 1.40% |
| Redmile Group LLCas of 31 Mar 2024 | 3.03m | 1.39% |
| Aisling Capital Management LPas of 31 Mar 2024 | 2.54m | 1.17% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
